Advaxis, Inc. ADXS-PSA Construct Causes Significant Tumor Regression in Preclinical Prostate Cancer Study

Published: Jun 13, 2012

PRINCETON, N.J.--(BUSINESS WIRE)--Advaxis, Inc., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced the publication of preclinical research with ADXS-PSA (ADXS31-142), Advaxis’ Lm-LLO immunotherapy targeting the PSA antigen associated with prostate cancer.

Back to news